Medivir is developing alovudine, an anti-HIV compound for the potential treatment of drug-resistant HIV infection. A phase IIa trial involving patients with multiresistant HIV was initiated in October 2001 and by July 2002, the trial had been completed.
RUSCONI, STEFANO (Primo)
|Parole Chiave:||Clinical Trials, Phase II as Topic; HIV Infections; Humans; Clinical Trials, Phase I as Topic; HIV Reverse Transcriptase; Dideoxynucleosides; HIV-1; Structure-Activity Relationship; Reverse Transcriptase Inhibitors|
|Settore Scientifico Disciplinare:||Settore MED/17 - Malattie Infettive|
|Data di pubblicazione:||feb-2003|
|Appare nelle tipologie:||01 - Articolo su periodico|